- Home
- LILAK vs ZLAB Comparison
LILAK vs ZLAB Comparison
Compare LILAK & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LILAK | ZLAB |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | Bermuda | China |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | LILAK | ZLAB |
|---|---|---|
| Price | $7.65 | $18.39 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $8.20 | ★ $57.22 |
| AVG Volume (30 Days) | 816.9K | ★ 841.3K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,433,000,000.00 | $441,629,000.00 |
| Revenue This Year | $1.62 | $26.16 |
| Revenue Next Year | N/A | $30.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.14 |
| 52 Week Low | $4.23 | $16.82 |
| 52 Week High | $9.13 | $44.34 |
Technical Indicators
Market Signals| Indicator | LILAK | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 32.29 | 40.35 |
| Support Level | $7.52 | $17.37 |
| Resistance Level | $8.36 | $19.01 |
| Average True Range (ATR) | 0.31 | 0.63 |
| MACD | -0.12 | 0.31 |
| Stochastic Oscillator | 6.67 | 57.51 |
Price Performance
Historical ComparisonAbout LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.